Sabinsa’s ForsLean® Gets PI Numbers From TGA To Enter Australian Market

July 12, 2010

Sabinsa Corporation has received Product Information (PI) numbers for ForsLean® 10% and 20% from Australia’s TGA (Therapeutic Goods Administration), a division of the Australian Government Department of Health and Ageing. Obtaining the PI numbers opens the way for ForsLean® to enter the Australian market. The numbers are:

11628 Sabinsa Coleus ForsLean®(1) 26/04/2005
107073 Sabinsa Coleus forskohlii extract 10%

Product Information (PI) provides health professionals with a summary of the essential scientific information about a therapeutic product, which requires information relating to its safe and effective use. Product Information documents are provided to and reviewed by the TGA as part of the approval process before a therapeutic product can be made available in Australia.

“As a global company we have become quite familiar with the process of meeting a variety of regulatory requirements in order to sell our products in many different markets,” said Sabinsa Marketing Director Shaheen Majeed. “Although the processes are never simple, we have extensive documentation on the safety and efficacy of our branded ingredients, so it’s just a matter of providing the right information in the right form.”

Sabinsa’s mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 20 years, Sabinsa has brought to market more than 100 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full time scientists conducting ongoing research in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. Most of our products intended for human consumption are certified Kosher, with many certified Halal. For more information, visit ,